NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

January 17, 2006 10:00 ET

Nymox Reports Completed Successful Studies of Saliva Test

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 17, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that studies have been successfully completed for the Company's saliva version of the NicAlert™ test for tobacco exposure. The studies were independently undertaken in general medical settings to assess the accuracy and utility of the saliva test. The Company's saliva test can be used without instruments and can be performed in minutes using several drops of saliva.

The independent research studies were carried out in family practice medical clinics under the supervision of principal investigators, Dr. N. Montalto and Dr. W. Wells. Dr. Montalto is a clinical expert in the field of tobacco use and dependency, and is Professor in the Department of Family Medicine at West Virginia University in Charleston, WV, and Director of the Freedom from Tobacco Use Program in Charleston. Dr. Wells is Principal Investigator and Medical Director of Clinical Research Centers of Tennessee in Lebanon, TN, with expertise in tobacco dependency.

The studies clearly showed that the saliva test is easily performed without training, and is accurate, reproducible and highly useful in the general medical setting. The full results from the studies will be presented at national meetings later this year and will also be published in the medical literature.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com